Top 50 global pharmaceutical and biotech companies by R&D intensity in 2017/2018
World's top 50 pharmaceutical and biotechnology companies based on R&D intensity in 2017/2018*
This statistic represents the worlds's top 50 pharmaceutical and biotechnology companies based on R&D intensity in 2017/2018. In that year, Tanvex Biopharma from Taiwan had the highest R&D intensity of over 800,000 percent. The R&D intensity is calculated from a company's R&D spending divided by the company's sales.
World's top 50 pharmaceutical and biotechnology companies based on R&D intensity in 2017/2018*
Loading statistic...
| R&D intensity | |
|---|---|
| Tanvex Biopharma | 821,643.6% |
| Obseva | 342,928.1% |
| Verona Pharma | 103,118.1% |
| Nantkwest | 88,322.1% |
| Endocyte | 82,756.3% |
| Regulus Therapeutics | 70,840.3% |
| TG Therapeutics | 67,287.9% |
| Bellicum Pharma | 35,393.7% |
| Intra-Cellular | 32,305.2% |
| Revance Therapeutics | 30,672.3% |
| Selecta Biosciences | 20,269.7% |
| Dynavax Technologies | 19,774% |
| Alder Biopharmaceuticals | 15,514.7% |
| Flexion Therapeutics | 14,431.3% |
| Clearside Biomedical | 14,118.3% |
| Vtv Therapeutics | 13,522% |
| Coherus Biosciences | 10,336.2% |
| Northwest Biotherapeutics | 9,874.7% |
| Ultragenyx Pharmaceutical | 8,749.8% |
| Isotechnika Pharma | 8,078.1% |
| Karyopharm Therapeutics | 6,583.7% |
| Ascendis Pharma | 6,463.3% |
| Idera Pharmaceuticals | 5,515.6% |
| Stemline Therapeutics | 5,493.5% |
| Cara Therapeutics | 5,246.2% |
| Tigenix | 5,031.6% |
| Syros Pharmaceuticals | 3,705.3% |
| Otonomy | 3,454.8% |
| Arcus Biosciences | 3,241.7% |
| Mesoblast | 2,877.5% |
| Unity Biotechnology | 2,704.3% |
| Immunomedics | 2,384.6% |
| Aclaris Therapeutics | 2,364.2% |
| Syndax Pharma | 2,286.6% |
| Dermira | 2,199.3% |
| Wave Life Sciences | 2,141.2% |
| Adverum Biotechnologies | 2,054.6% |
| Proqr Therapeutics | 1,720.2% |
| Spero Therapeutics | 1,660.9% |
| Ocular | 1,605.8% |
| Foamix Pharmaceuticals | 1,574.8% |
| Ab Science | 1,537.3% |
| Dicerna Pharmaceuticals | 1,382.6% |
| Gw Pharmaceuticals | 1,343.8% |
| Theravance Biopharma | 1,130.2% |
| Chimerix | 1,100.3% |
| Epizyme | 996.6% |
| Spark Therapeutics | 952.8% |
| Tetraphase Pharmaceuticals | 952.2% |
| Rigel Pharmaceuticals | 931.9% |
Source
More information
Statistics on "Biotech industry"
Discover Statista
Need help with using Statista for your research?
Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Statistics
- Top pharma and biotech companies by sales growth in 2017-2018
- Leading UK pharmaceutical and biotechnology companies ranked by market value 2015
- Italy: number of statements about pharmaceuticals 2019, by brand
- Value of M&A transactions in biotechnology and pharmaceuticals sector 1985-2018
- Number of M&A transactions in biotechnology and pharmaceuticals sector 1985-2018
- Projection of top 10 global pharmaceutical companies by revenue 2019
- Projected top pharmaceutical companies based on new sales 2018-2019
- Enterprise value of top companies in non-oncology rare disease therapeutics 2017
- Top global generic pharmaceutical companies, by enterprise value 2016
- Top global generic pharmaceutical companies 2015, by revenue
- US adults who believe research results have an influence the US pharma industry
- Enterprise value of generic pharmaceutical companies with a U.S. presence 2016
- U.S. generic pharmaceutical industry top acquisitions 2015
- Enterprise value of generic pharmaceutical companies with a U.S. presence 2016
- Worldwide median pharmaceutical M&A value to revenue multiple 2011-2015
- Astellas Pharma's employee numbers FY 2014-2017
- Chile: top pharma companies in 2018, by index score
- R&D investment value in bioindustry in South Korea 2016, by sector
- Forbes selected biotech companies in China & Hong Kong 2017, based on market value
- Chemical companies - revenue per employee 2004-2009
Statistics on "Biotech industry"
Related topics
About Statista
